Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979973 | 0.93 | ALDH1A1 (0.44) | LMNAADRB2ADRB1ADRB3HTT | |
| SCHEMBL1978866 | 0.86 | LMNA (0.49) | LMNAF2SLC6A3HTTALDH1A1 | |
| SCHEMBL1982389 | 0.86 | LMNA (0.42) | LMNAF2SLC6A3ADRB2ADRB1 | |
| SCHEMBL15093271 | 0.85 | TSHR (0.43) | LMNAADRB2ADRB1ADRB3HTT | |
| SCHEMBL1981726 | 0.85 | LMNA (0.47) | LMNAF2SLC6A3ADRB2ADRB1 | |
| SCHEMBL1913773 | 0.83 | SLC6A3 (0.56) | LMNAF2SLC6A3ALDH1A1TSHR | |
| SCHEMBL1981542 | 0.83 | LMNA (0.45) | LMNAF2SLC6A3ADRB2ADRB1 | |
| SCHEMBL1979142 | 0.83 | LMNA (0.45) | LMNAF2SLC6A3HTTALDH1A1 | |
| SCHEMBL1979966 | 0.83 | ELANE (0.48) | LMNAF2SLC6A3HTTALDH1A1 | |
| SCHEMBL15093223 | 0.81 | TSHR (0.37) | LMNAADRB2ADRB1ADRB3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | claimed |
| EP-2509569-B1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RES & DEV (FR) | 2013-12-04 | — | — | EP | claimed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | claimed |
| EP-2509569-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | claimed |
| CN-102740826-A | Novel peroxide derivatives, method for the production thereof and use thereof in human medicine and in cosmetics for the treatment or prevention of acne | GALDERMA RES & DEV | 2012-10-17 | — | — | CN | claimed |
| WO-2011070171-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | claimed |
| US-8729312-B2 | Derivatives of novel peroxides, method of preparation thereof and use thereof in human medicine as well as in cosmetics for the treatment or prevention of acne | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-05-20 | — | — | US | disclosed |
| EP-2509569-B1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RES & DEV (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-2509569-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| CN-102740826-A | Novel peroxide derivatives, method for the production thereof and use thereof in human medicine and in cosmetics for the treatment or prevention of acne | GALDERMA RES & DEV | 2012-10-17 | — | — | CN | disclosed |
| WO-2011070171-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178648-A1 | DERIVATIVES OF NOVEL PEROXIDES, METHOD OF PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AS WELL AS IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE | GPX4, LPO, GPX1 | LMNA 2502/4885F2 685/4885SLC6A3 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.